Get started
Author

Dunja Urosev

Observed names: D. Urosev, Urosev, Dunja
Institution: Zymeworks (Canada)
ORCID: 0009-0002-6679-028X
Observed ORCID: 0009-0002-6679-028X
OpenAlex ID: A5072941072
Structure of the N‐terminal half of gelsolin bound to actin: roles in severing, apoptosis and FAF
2004 · Leslie D Burtnick, Dunja Urosev, et al. · The EMBO Journal · 141
PDF
The Role of Hydration in Protein Stability: Comparison of the Cold and Heat Unfolded States of Yfh1
2012 · Miquel Adrover, Gabriel Martorell, et al. · Journal of Molecular Biology · 62
PDF
From the first to the second domain of gelsolin: a common path on the surface of actin?1
2003 · Edward Irobi, Leslie D. Burtnick, et al. · FEBS Letters · 43
PDF
EsiB, a Novel Pathogenic Escherichia coli Secretory Immunoglobulin A-Binding Protein Impairing Neutrophil Activation
2013 · Ilaria Pastorello, Silvia Rossi Paccani, et al. · mBio · 28
Activation in isolation: exposure of the actin‐binding site in the C‐terminal half of gelsolin does not require actin1
2003 · Kartik Narayan, Sakesit Chumnarnsilpa, et al. · FEBS Letters · 28
The Structure of Gelsolin Bound to ATP
2006 · Dunja Urosev, Qing Ma, et al. · Journal of Molecular Biology · 20
Calcium Ion Exchange in Crystalline Gelsolin
2006 · Sakesit Chumnarnsilpa, Anantasak Loonchanta, et al. · Journal of Molecular Biology · 17
PDF
Crystal structure of c5321: a protective antigen present in uropathogenic Escherichia coli strains displaying an SLR fold
2013 · Dunja Urosev, Mario Ferrer-Navarro, et al. · BMC Structural Biology · 15
PDF
Localization of calponin binding sites in the structure of 90 kDa heat shock protein (Hsp90)
1999 · Natalia V Bogatcheva, YuShu Ma, et al. · FEBS Letters · 11
Abstract 2658: ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
2023 · Laurence Madera, Andrea Hernández Rojas, et al. · Cancer Research · 6
Abstract 2641: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
2023 · Sam Lawn, Andrea Hernandez Rojas, et al. · Cancer Research · 3
Abstract 1533: ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
2023 · Andrea Hernandez Rojas, Jodi Wong, et al. · Cancer Research · 3
Abstract 2052: Screening novel format antibodies to design bispecific ADCs that address target heterogeneity
2024 · Stuart D. Barnscher, Dunja Urosev, et al. · Cancer Research · 2
ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al. · Clinical Cancer Research · 1
Abstract 2874: ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload
2025 · Dunja Urosev, Saki Konomura, et al. · Cancer Research · 1
6 Oral: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
2024 · A. Hernandez, D. Urosev, et al. · European Journal of Cancer · 1
177 (PB165): ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models
2024 · L. Madera, A. Wu, et al. · European Journal of Cancer · 1
Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications
2024 · Sam Lawn, Andrea Hernandez Rojas, et al. · Cancer Research · 1
Supplementary Figure S1 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Data from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S10 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S2 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S7 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S12 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Works count: 46
Citation count: 384
H-index: 9
I10-index: 9
Year
Topic
Type